Quick Takeaways
- Nantahala Capital Management, LLC filed SCHEDULE 13G/A for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 5.7%.
- Date of event: 31 Dec 2025.
Nantahala Capital Management, LLC - 31 Dec 2025 SCHEDULE 13G/A Report for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT)
- Filing Manager
- Nantahala Capital Management, LLC
- Reporting Manager
- Nantahala Capital Management, LLC
- Symbol
- IKT
- Shares outstanding
- 123,906,972 shares
- Disclosed Ownership
- 7,037,916 shares
- Ownership
- 5.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 17:04:43 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Nantahala Capital Management, LLC disclosed 5.7% ownership in INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 13 Feb 2026, 17:04.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 5.7% | 7,037,916 | 0 | 7,037,916 | /s/ Taki Vasilakis | Taki Vasilakis / Chief Compliance Officer | |
| Wilmot B. Harkey | 5.7% | 7,037,916 | 0 | 7,037,916 | /s/ Wilmot B. Harkey | Wilmot B. Harkey | |
| Daniel Mack | 5.7% | 7,037,916 | 0 | 7,037,916 | /s/ Daniel Mack | Daniel Mack |